138 related articles for article (PubMed ID: 2004024)
1. Correlation of serological, quantitative and cell-mediated functional assays of maternal alloantibodies with the severity of haemolytic disease of the newborn.
Hadley AG; Kumpel BM; Leader KA; Poole GD; Fraser ID
Br J Haematol; 1991 Feb; 77(2):221-8. PubMed ID: 2004024
[TBL] [Abstract][Full Text] [Related]
2. Protection against immune haemolytic disease of newborn infants by maternal monocyte-reactive IgG alloantibodies (anti-HLA-DR).
Dooren MC; Kuijpers RW; Joekes EC; Huiskes E; Goldschmeding R; Overbeeke MA; von dem Borne AE; Engelfriet CP; Ouwehand WH
Lancet; 1992 May; 339(8801):1067-70. PubMed ID: 1349101
[TBL] [Abstract][Full Text] [Related]
3. Results of tests with different cellular bioassays in relation to severity of RhD haemolytic disease. Report from nine collaborating laboratories.
Vox Sang; 1991; 60(4):225-9. PubMed ID: 1926829
[TBL] [Abstract][Full Text] [Related]
4. Serological and immunological characteristics of maternal anti-Rh(D) antibodies in predicting the severity of haemolytic disease of the newborn.
Zupańska B; Brojer E; Richards Y; Lenkiewicz B; Seyfried H; Howell P
Vox Sang; 1989; 56(4):247-53. PubMed ID: 2503936
[TBL] [Abstract][Full Text] [Related]
5. Evidence for the protective effect of maternal FcR-blocking IgG alloantibodies HLA-DR in Rh D-haemolytic disease of the newborn.
Dooren MC; van Kamp IL; Kanhai HH; Gravenhorst JB; von dem Borne AE; Engelfriet CP
Vox Sang; 1993; 65(1):55-8. PubMed ID: 8362515
[TBL] [Abstract][Full Text] [Related]
6. What is the best predictor of the severity of ABO-haemolytic disease of the newborn?
Brouwers HA; Overbeeke MA; van Ertbruggen I; Schaasberg W; Alsbach GP; van der Heiden C; van Leeuwen EF; Stoop JW; Engelfriet CP
Lancet; 1988 Sep; 2(8612):641-4. PubMed ID: 2901516
[TBL] [Abstract][Full Text] [Related]
7. Maternal antibodies against fetal blood group antigens A or B: lytic activity of IgG subclasses in monocyte-driven cytotoxicity and correlation with ABO haemolytic disease of the newborn.
Brouwers HA; Overbeeke MA; Ouwehand WH; Keuning K; van Ertbruggen I; van Leeuwen EF; Stoop JW; Engelfriet CP
Br J Haematol; 1988 Dec; 70(4):465-9. PubMed ID: 3219297
[TBL] [Abstract][Full Text] [Related]
8. Prediction of the severity of haemolytic disease of the newborn. Quantitative IgG anti-D subclass determinations explain the correlation with functional assay results.
Garner SF; Gorick BD; Lai WY; Brown D; Taverner J; Hughes-Jones NC; Contreras M; Lubenko A
Vox Sang; 1995; 68(3):169-76. PubMed ID: 7625074
[TBL] [Abstract][Full Text] [Related]
9. Laboratory assays for predicting the severity of haemolytic disease of the fetus and newborn.
Hadley AG
Transpl Immunol; 2002 Aug; 10(2-3):191-8. PubMed ID: 12216949
[TBL] [Abstract][Full Text] [Related]
10. Mononuclear phagocyte assays, autoanalyzer quantitation and IgG subclasses of maternal anti-RhD in the prediction of the severity of haemolytic disease in the fetus before 32 weeks gestation.
Garner SF; Wiener E; Contreras M; Nicolini U; Kochenour N; Letsky E; Rodeck CH
Br J Haematol; 1992 Jan; 80(1):97-101. PubMed ID: 1536816
[TBL] [Abstract][Full Text] [Related]
11. A quantitative assay for subclassing IgG alloantibodies implicated in hemolytic disease of the newborn.
Thomas NC; Shirey RS; Blakemore K; Kickler TS
Vox Sang; 1995; 69(2):120-5. PubMed ID: 8585192
[TBL] [Abstract][Full Text] [Related]
12. The use of interferon-gamma-treated U937 cells in chemiluminescence assays to detect red cell, platelet and granulocyte antibodies of potential clinical significance.
Hadley AG; Poole GD; Amphlett NW; Lucas GF
Clin Lab Haematol; 1992; 14(4):315-26. PubMed ID: 1478011
[TBL] [Abstract][Full Text] [Related]
13. Predicting hemolytic disease of the newborn: a comparison of the monocyte monolayer assay and the chemiluminescence test.
Lucas GF; Hadley AG; Nance SJ; Garratty G
Transfusion; 1993 Jun; 33(6):484-7. PubMed ID: 8516790
[TBL] [Abstract][Full Text] [Related]
14. Predicting the severity of haemolytic disease of the newborn: an assessment of the clinical usefulness of the chemiluminescence test.
Noble AL; Poole GD; Anderson N; Lucas GF; Hadley AG
Br J Haematol; 1995 Jul; 90(3):718-20. PubMed ID: 7647017
[TBL] [Abstract][Full Text] [Related]
15. Assessment of severity of haemolytic disease of newborn by monocyte monolayer assay.
Dhingra-Kumar N; Duguid JK; Bromilow IM
Indian J Med Res; 1995 Aug; 102():71-6. PubMed ID: 8834817
[TBL] [Abstract][Full Text] [Related]
16. Quantitative and functional asessment of anti-RhD: a comparative study of non-invasive methods in antenatal prediction of Rh hemolytic disease.
Filbey D; Garner SF; Hadley AG; Shepard SL
Acta Obstet Gynecol Scand; 1996 Feb; 75(2):102-7. PubMed ID: 8604593
[TBL] [Abstract][Full Text] [Related]
17. A comparison of in vitro tests for predicting the severity of haemolytic disease of the fetus and newborn.
Hadley AG
Vox Sang; 1998; 74 Suppl 2():375-83. PubMed ID: 9704470
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of red cell maternal antibodies by chemiluminescence.
Downing I; Bromilow IM; Templeton JG; Fraser RH
Vox Sang; 1996; 71(4):226-32. PubMed ID: 8958647
[TBL] [Abstract][Full Text] [Related]
19. Prediction of the outcome of rhesus haemolytic disease of the newborn: additional information using an ADCC assay.
Urbaniak SJ; Greiss MA; Crawford RJ; Fergusson MJ
Vox Sang; 1984; 46(5):323-9. PubMed ID: 6730428
[TBL] [Abstract][Full Text] [Related]
20. An enzyme-linked immunosorbent assay for the quantitation of IgG anti-D and IgG subclasses in the sera of alloimmunized patients.
Lambin P; Ahaded A; Debbia M; Lauroua P; Rouger P
Transfusion; 1998 Mar; 38(3):252-61. PubMed ID: 9563405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
